1. Home
  2. Directory
  3. California
  4. Duarte
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1861692485

IBRAHIM TAHA ALDOSS M.D.
Prescription History 1861692485
Internal Medicine - Hematology in Duarte, CA


Quality Rating: 99.12 out of 100 score

NPI Status: Active since July 21, 2007

Contact Information

1500 E. DUARTE RD.
DEPARTMENT OF HEMATOLOGY & HCT
DUARTE, CA
ZIP 91010
Phone: (626) 256-4673

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IBRAHIM TAHA ALDOSS M.D., an active Hematology specialist practicing in Duarte, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 86 documented patient claims. Among these therapy options, the most frequently utilized medication is Jakafi, which accounts for 41 claims alone.

Medication Index

J
R
S
T
No matching medications currently found on file.

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,222
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply804
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $571,550.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,940.25

State Avg Cost Per Claim

$15,930.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
CA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.7
Peer Average Days Supply1,011
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216,218.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,018.23

State Avg Cost Per Claim

$18,322.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Scemblix

Generic Formulation: Asciminib HydrochlorideSpecialty: Hematology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.8
Peer Average Days Supply523
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $271,859.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,654.94

State Avg Cost Per Claim

$22,113.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Hematology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 588
CA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.1
Peer Average Days Supply450
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 40.0% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $142,827.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,801.30

State Avg Cost Per Claim

$15,310.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like IBRAHIM TAHA ALDOSS M.D. provides transparency into local medical care patterns within Duarte, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.